PRTC
MCID: PRT010
MIFTS: 63

Parathyroid Carcinoma (PRTC) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Parathyroid Carcinoma

About this section

Aliases & Descriptions for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma 52 11 48 54 70 12 50 13
Parathyroid Cancer 48 27 50
Malignant Tumor of Parathyroid Gland 11 68
Parathyroid Gland Adenocarcinoma 11 68
Parathyroid Gland Neoplasm 11 27
Parathyroid Neoplasms 39 68
Malignant Neoplasm of Parathyroid Gland 11
 
Malignant Neoplasm of the Parathyroid 11
Carcinoma of Parathyroid Gland 11
Neoplasm of Parathyroid Gland 11
Parathyroid Gland Cancer 11
Parathyroid Neoplasm 11
Prtc 70

Characteristics:

Orphanet epidemiological data:

54
parathyroid carcinoma:
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adult; Age of death: adult,elderly

HPO:

64
parathyroid carcinoma:
Inheritance: autosomal dominant inheritance, somatic mutation

Classifications:



External Ids:

OMIM52 608266
Disease Ontology11 DOID:1540
ICD1030 C75.0
ICD9CM32 194.1
MeSH39 D010282
Orphanet54 ORPHA143
ICD10 via Orphanet31 C75.0
MedGen37 C0687150

Summaries for Parathyroid Carcinoma

About this section
UniProtKB/Swiss-Prot:70 Parathyroid carcinoma: These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

MalaCards based summary: Parathyroid Carcinoma, also known as parathyroid cancer, is related to parathyroid cancer, childhood and cdc73-related parathyroid carcinoma, and has symptoms including Array, Array and Array. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Transcription_Role of VDR in regulation of genes involved in osteoporosis. Affiliated tissues include the parathyroid gl, bone and thyroid, and related mouse phenotypes are endocrine/exocrine gland and integument.

Disease Ontology:11 An endocrine gland cancer located in the parathyroid glands located in the neck.

Wikipedia:71 Parathyroid carcinoma is a rare malignant neoplasm resulting in parathyroid adenoma to carcinoma... more...

Description from OMIM:52 608266

Related Diseases for Parathyroid Carcinoma

About this section

Diseases in the Parathyroid Carcinoma family:

Cdc73-Related Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 79)
idRelated DiseaseScoreTop Affiliating Genes
1parathyroid cancer, childhood11.9
2cdc73-related parathyroid carcinoma11.8
3hyperparathyroidism-jaw tumor syndrome11.2
4hyperparathyroidism10.4
5deafness, autosomal recessive 4210.2CALCA, CASR
6stickler syndrome10.2CALCA, PTH
7adenoma10.2
8hypophosphatasia, adult10.2CALCA, PTH
9atrial heart septal defect10.2CALCA, PTH
10striatonigral degeneration10.2CASR, PTH
11acrorenal syndrome10.2CALCA, PTH
12axial osteomalacia10.2CALCA, CDC73
13gastric antral vascular ectasia10.1CASR, PTH
14restless legs syndrome 710.1CDC73, MEN1
15toenail dystrophy, isolated10.1CALCA, PTH
16ovarian endometrioid cystadenoma10.1CALCA, PTH
17parathyroid adenoma10.1
18pemphigus foliaceus10.1CALCA, MEN1
19paranasal sinus cancer, adult10.1CALCA, MEN1
20nodular prostate10.1CALCA, LGALS3
21hirschsprung disease 110.1CALCA, MEN1
22gemistocytic astrocytoma10.1CALCA, MEN1
23weill-marchesani syndrome10.1CASR, PTH
24cowden syndrome 310.1CALCA, MEN1
25macular holes10.1MEN1, PTH
26cardioauditory syndrome of sanchez cascos10.1CALCA, MEN1
27keloids10.1CALCA, MEN1
28mediastinitis10.1
29strabismus10.1MEN1, PTH
30caroli disease10.1CCND1, CDC73
31familial chronic myelocytic leukemia-like syndrome10.1CASR, CDC73, PTH
32mesenchymal cell neoplasm10.0CALCA, CASR, PTH
33cartilage disease10.0CALCA, UCHL1
34waardenburg syndrome, type 4b10.0CALCA, CASR, PTH
35pes anserinus tendinitis or bursitis10.0CALCA, CASR, PTH
36tinea unguium10.0CALCA, CASR, PTH
37popliteal pterygium syndrome, bartsocas-papas type10.0CCND1, LGALS3
38pre-eclampsia10.0CALCA, CASR, PTH
39indian tick typhus10.0CALCA, CASR, PTH
40aflatoxins-related hepatocellular carcinoma10.0CALCA, PTH
41peritoneal serous papillary adenocarcinoma10.0CALCA, LGALS3
42thyroiditis10.0
43aneurysm10.0CALCA, MEN1
44neuroretinitis10.0CCND1, MEN1
45dysbaric osteonecrosis10.0CALCA, PTH
46immune system organ benign neoplasm10.0CDC73, MEN1, PTH
47adult ependymoblastoma10.0CALCA, MEN1, PTH
48peritoneal mesothelioma9.9CALCA, CCND1, LGALS3
49benign shuddering attacks9.9CALCA, LGALS3, MEN1
50muscular dystrophy-dystroglycanopathy , type a, 109.9CALCA, LGALS3, MEN1

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):


Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:



Diseases related to parathyroid carcinoma

Symptoms & Phenotypes for Parathyroid Carcinoma

About this section


Clinical features from OMIM:

608266

Human phenotypes related to Parathyroid Carcinoma:

 54 64 (show all 38)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypercalcemia64 54 Obligate (100%) HP:0003072
2 parathyroid carcinoma64 54 Obligate (100%) HP:0006780
3 primary hyperparathyroidism64 54 Obligate (100%) HP:0008200
4 hypophosphatemia64 54 Very frequent (99-80%) HP:0002148
5 hypercalciuria64 54 Very frequent (99-80%) HP:0002150
6 elevated circulating parathyroid hormone level64 54 Very frequent (99-80%) HP:0003165
7 abnormality of the parathyroid morphology54 Very frequent (99-80%)
8 nephrocalcinosis64 54 Frequent (79-30%) HP:0000121
9 uterine leiomyoma64 54 Frequent (79-30%) HP:0000131
10 nephrolithiasis64 54 Frequent (79-30%) HP:0000787
11 osteoporosis64 54 Frequent (79-30%) HP:0000939
12 hoarse voice64 54 Frequent (79-30%) HP:0001609
13 weight loss64 54 Frequent (79-30%) HP:0001824
14 polydipsia64 54 Frequent (79-30%) HP:0001959
15 dysphagia64 54 Frequent (79-30%) HP:0002015
16 infantile hypercalcemia64 54 Frequent (79-30%) HP:0008250
17 fibroma64 54 Frequent (79-30%) HP:0010614
18 shortened qt interval64 54 Frequent (79-30%) HP:0012232
19 fatigue64 54 Frequent (79-30%) HP:0012378
20 renal insufficiency64 54 Occasional (29-5%) HP:0000083
21 renal cyst64 54 Occasional (29-5%) HP:0000107
22 chondrocalcinosis64 54 Occasional (29-5%) HP:0000934
23 muscle weakness64 54 Occasional (29-5%) HP:0001324
24 pancreatitis64 54 Occasional (29-5%) HP:0001733
25 nausea and vomiting64 54 Occasional (29-5%) HP:0002017
26 constipation64 54 Occasional (29-5%) HP:0002019
27 headache64 54 Occasional (29-5%) HP:0002315
28 episodic abdominal pain64 54 Occasional (29-5%) HP:0002574
29 bone pain64 54 Occasional (29-5%) HP:0002653
30 peptic ulcer64 54 Occasional (29-5%) HP:0004398
31 renal hamartoma64 54 Occasional (29-5%) HP:0008696
32 mandibular pain64 54 Occasional (29-5%) HP:0200025
33 nephroblastoma64 54 Very rare (<4-1%) HP:0002667
34 thyroid carcinoma64 54 Very rare (<4-1%) HP:0002890
35 pancreatic adenocarcinoma64 54 Very rare (<4-1%) HP:0006725
36 testicular neoplasm64 54 Very rare (<4-1%) HP:0010788
37 lipoma64 54 Very rare (<4-1%) HP:0012032
38 hyperparathyroidism64 HP:0000843

MGI Mouse Phenotypes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053799.2CASR, CCND1, CDC73, MEN1, PTH
2MP:00107718.8CASR, CCND1, CDC73, LGALS3, UCHL1
3MP:00053878.7CASR, CCND1, CDC73, LGALS3, MEN1, PTH
4MP:00053978.4CASR, CCND1, CDC73, LGALS3, PTH, UCHL1
5MP:00053818.3CASR, CCND1, CDC73, LGALS3, MEN1, UCHL1
6MP:00053858.3CCND1, CDC73, LGALS3, MEN1, PTH, UCHL1
7MP:00053907.9CASR, CCND1, LGALS3, PTH, UCHL1
8MP:00053767.9CASR, CCND1, CDC73, LGALS3, MEN1, PTH
9MP:00107687.8CASR, CCND1, CDC73, LGALS3, MEN1, PTH

Drugs & Therapeutics for Parathyroid Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Sensipar16 CINACALCET HYDROCHLORIDE Amgen March 2004
FDA Label: Sensipar
Disease/s that Drug Treats:Hyperparathyroidism / Hypercalcemia
Indications and Usage:16 Sensipar is a calcium-sensing receptor agonist indicated for: concentration time curve) is increased in patients with moderate and Secondary Hyperparathyroidism (HPT) in adult patients with chronic severe hepatic impairment. Patients should be closely monitored forkidney disease (CKD) on dialysis. (1.1) serum calcium, serum phosphorus, and iPTH levels throughout Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). (1.2) treatment. (5.3, 8.7) Hypercalcemia in adult patients with primary HPT for whomparathyroidectomy would be indicated on the basis of serum calciumlevels, but who are unable to undergo parathyroidectomy. (1.3)
DrugBank Targets:14 1. Extracellular calcium-sensing receptor
Mechanism of Action:16 
Target: calcium-sensing receptor
Action: increases sensitivity to activation by extracellular calcium
FDA: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulatorof PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, directly lowers PTH levels byincreasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH isassociated with a concomitant decrease in serum calcium levels.

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 169)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BenzocaineapprovedPhase 4, Phase 220161994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
2
Zoledronic acidapprovedPhase 4, Phase 3, Phase 1294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
3
Betamethasoneapproved, vet_approvedPhase 4195378-44-99782
Synonyms:
.beta.-Methasone
.beta.-Methasone alcohol
1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
24024-03-1
34166_FLUKA
34166_RIEDEL
378-44-9
4-08-00-03501 (Beilstein Handbook Reference)
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-16.beta.-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16β-methylprednisolone
9-alpha-Fluoro-16-beta-methylprednisolone
9.alpha.-Fluoro-16.beta.-methylprednisolone
9alpha-Fluoro-16 beta-methyl-prednisolone
9alpha-Fluoro-16beta-methylprednisolone
9α-Fluoro-16β-methylprednisolone
AC1L1EYE
AC1L1TT4
AC1Q5HJZ
AKOS001582690
AR-1A7284
AR-1H5595
B1837
B7005_SIAL
B7005_SIGMA
B9675_SIAL
BIDD:PXR0047
BPBio1_000533
BRD-A35108200-001-04-7
BRD-K39188321-001-03-9
BRN 3176546
BSPBio_000483
Bebate
Becort
Bedifos
Betacorlan
Betacortril
Betadexamethasone
Betafluorene
Betamamallet
Betametasona
Betametasona [INN-Spanish]
Betametasone
Betametasone [DCIT]
Betamethasone
Betamethasone (JP15/USP/INN)
Betamethasone Base
Betamethasone Valearate
Betamethasone [USAN:BAN:INN:JAN]
Betamethasone [USAN:INN:BAN:JAN]
Betamethasone alcohol
Betamethasone cream
Betamethasonum
Betamethasonum [INN-Latin]
Betamethasonvalerat Mikron
Betamethazone
Betapredol
Betasolon
Betnelan
 
Betsolan
C22H29FO5
CHEBI:3077
CHEMBL632
CID3003
CID9782
CPD000339803
Celestene
Celeston
Celestona
Celestone
Celestone Syrup and Tablets
Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone
Cellestoderm
Cidoten
D00244
D1961
DB00443
Desacort-Beta
EINECS 206-825-4
Flubenisolone
HMS1569I05
HSDB 3015
Hormezon
I06-0121
KST-1A3042
LS-118466
LT00441022
Luxiq
Luxiqo
MLS-0310139.0001
MLS000686794
MLS000859943
MLS001066413
MLS001332616
MLS002153244
Methazon
MolPort-003-845-025
MolPort-007-981-051
NCGC00164401-01
NCGC00164401-02
NSC 39470
NSC-39470
NSC39470
Prestwick0_000362
Prestwick1_000362
Prestwick2_000362
Prestwick3_000362
Prestwick_703
Rinderon
Rinderon (TN)
Rinderon A
S1500_Selleck
SAM002589959
SCH 4831
SCH-4831
SMP1_000043
SMR000058601
SMR000339803
SPBio_002404
UNII-9842X06Q6M
Valisone
Visubeta
ZINC03876136
beta-Methasone
beta-Methasone alcohol
betamethasone
4
Glycerolexperimental, approvedPhase 423856-81-5753
Synonyms:
1,2,3-Trihydroxypropane
1,2,3-propanetriol
1,2,3-trihydroxypropane
Bulbold
Cristal
E 422
Emery 916
Glyceol Opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
Glycerinum
 
Glyceritol
Glycerol
Glycyl alcohol
Glyrol
Glysanin
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
5
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
6tannic acidapproved, NutraceuticalPhase 4, Phase 22016
7
Cholecalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 287567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
Colecalciferol
 
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D-3
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
cholecalciferol
colecalciferolum
vitamin d-3
8
Alfacalcidolapproved, nutraceuticalPhase 46141294-56-85282181
Synonyms:
(5Z,7e)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
1-Hydroxycholecalciferol
1-hydroxycholecalciferol
1alpha-Hydroxy-vitamin D3
 
1alpha-hydroxycholecalciferol
1alpha-hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
Alfacalcidolum
Alsiodol
9
Calcitriolapproved, nutraceuticalPhase 4, Phase 3, Phase 221032222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
Ambap32222-06-3
 
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
10Pharmaceutical SolutionsPhase 4, Phase 2, Phase 38192
11ErgocalciferolsPhase 4, Phase 3, Phase 2, Phase 11281
12HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 114415
13Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15713
14Calcimimetic AgentsPhase 4, Phase 2, Phase 3, Phase 171
15VitaminsPhase 4, Phase 2, Phase 3, Phase 15282
16Cinacalcet HydrochloridePhase 4, Phase 2, Phase 3, Phase 171
17Trace ElementsPhase 4, Phase 3, Phase 2, Phase 16001
18Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113180
19MicronutrientsPhase 4, Phase 3, Phase 2, Phase 16001
20Bone Density Conservation AgentsPhase 4, Phase 3, Phase 2, Phase 13376
21Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113168
22vitamin dPhase 4, Phase 2, Phase 3, Phase 11724
23HematinicsPhase 4, Phase 21684
24
s 1 (combination)Phase 4, Phase 2378
Synonyms:
 
Gimeracil / oteracil / tegafur
TS 1
25Vasoconstrictor AgentsPhase 4, Phase 3, Phase 22122
26CalcifediolPhase 4, Phase 3, Phase 15019356-17-3
27DiphosphonatesPhase 4, Phase 3, Phase 2450
28HydroxycholecalciferolsPhase 4, Phase 3129
291 alpha-hydroxyergocalciferolPhase 4, Phase 3, Phase 125
30AnticoagulantsPhase 42623
31Chelating AgentsPhase 41423
32Ferric CompoundsPhase 4194
33Respiratory System AgentsPhase 44997
34Anti-Inflammatory AgentsPhase 410729
35Betamethasone acetatePhase 48
36Anti-Asthmatic AgentsPhase 43488
37glucocorticoidsPhase 45103
38Betamethasone benzoatePhase 4195
39Betamethasone sodium phosphatePhase 4195
40Betamethasone-17,21-dipropionatePhase 4195
41Betamethasone ValeratePhase 41952152-44-5
42HepcidinsPhase 456
43Vitamin D2NutraceuticalPhase 4, Phase 3, Phase 2, Phase 11281
44CalciferolNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11383
45CitrateNutraceuticalPhase 41160
46
Citric Acidnutraceutical, vet_approvedPhase 4116077-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
47OliveNutraceuticalPhase 4278
48
DenosumabapprovedPhase 3, Phase 2, Phase 1138615258-40-7
Synonyms:
615258-40-7
AMG-162
D03684
Denosumab
 
Denosumab (USAN)
Denosumab (genetical recombination)
Denosumab (genetical recombination) (JAN)
Prolia
Xgeva
49
Calcium carbonateapprovedPhase 3215471-34-1
Synonyms:
CaCO3
Calcium carbonate
Calcium carbonate (1:1)
Calciumcarbonat
Carbonate de calcium
 
Carbonato de calcio
Carbonic acid calcium salt (1:1)
E 170
Kalziumkarbonat
Kohlensaurer kalk
Precipitated calcium carbonate
50Gastrointestinal AgentsPhase 3, Phase 28402

Interventional clinical trials:

(show top 50)    (show all 182)
idNameStatusNCT IDPhase
1Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis PatientsUnknown statusNCT02338934Phase 4
2A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid CancerCompletedNCT00037518Phase 4
3Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone MetastasesCompletedNCT00219219Phase 4
4Initial Dosing of Paricalcitol in Secondary HyperparathyroidismCompletedNCT00307840Phase 4
5Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisCompletedNCT01181531Phase 4
6Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH LevelCompletedNCT01101113Phase 4
7Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.CompletedNCT01939977Phase 4
8ACHIEVE: Optimizing the Treatment of Secondary HyperparathyroidismCompletedNCT00135304Phase 4
9Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary HyperparathyroidismCompletedNCT01115543Phase 4
10Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin DCompletedNCT00977080Phase 4
11Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial DoseCompletedNCT00891813Phase 4
12START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
13Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary HyperparathyroidismCompletedNCT00123461Phase 4
14Vitamin D Deficiency in Chronic Kidney Disease (CKD) PatientsCompletedNCT00958451Phase 4
15Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal TransplantationCompletedNCT01178450Phase 4
16Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on DialysisCompletedNCT00537979Phase 4
17A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® InjectionCompletedNCT00463021Phase 4
18Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)CompletedNCT00823303Phase 4
1920070360 Incident DialysisCompletedNCT00803712Phase 4
20Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in HypoparathyroidismRecruitingNCT02910466Phase 4
21Steroids in the Postoperative Transient Hypoparathyroidism Total ThyroidectomyRecruitingNCT02652884Phase 4
22A Study of Ferric Citrate to Improve Inflammation and Lipid LevelsRecruitingNCT02661295Phase 4
23Intravenous Paricalcitol in Chronic Hemodialysis PatientsActive, not recruitingNCT03023748Phase 4
24Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis PatientsActive, not recruitingNCT02214563Phase 4
25Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPTNot yet recruitingNCT03123406Phase 4
26Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsTerminatedNCT00664430Phase 4
27Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisTerminatedNCT00446329Phase 4
28Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)Unknown statusNCT01479088Phase 2, Phase 3
29An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary HyperparathyroidismCompletedNCT01460030Phase 3
30Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 3
31Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to EtelcalcetideCompletedNCT01932970Phase 3
32The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone LossCompletedNCT00375505Phase 3
33A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on DialysisCompletedNCT00042653Phase 3
34Phase 3 Study of KHK7580CompletedNCT02549391Phase 2, Phase 3
35Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South CarolinaCompletedNCT00412087Phase 3
36Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismCompletedNCT01341782Phase 3
37Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3
38Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3
39Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedNCT02282813Phase 3
40Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetCompletedNCT01896232Phase 3
41Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT01785849Phase 3
42Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01788046Phase 3
43Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01785875Phase 3
44Calcium and Vitamin D Malnutrition in Elderly WomenCompletedNCT00352170Phase 3
45Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)CompletedNCT01219855Phase 2, Phase 3
46A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis PatientsCompletedNCT00037635Phase 3
47Single-arm Extension Study on the Safety of Cinacalcet Treatment in SHPT in Pediatric Subjects With CKD on DialysisCompletedNCT02341417Phase 3
48SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismCompletedNCT00117052Phase 3
49The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)CompletedNCT02328404Phase 3
50Phase 3 Study of KHK7580RecruitingNCT02549417Phase 3

Search NIH Clinical Center for Parathyroid Carcinoma


Cochrane evidence based reviews: parathyroid neoplasms

Genetic Tests for Parathyroid Carcinoma

About this section

Genetic tests related to Parathyroid Carcinoma:

id Genetic test Affiliating Genes
1 Parathyroid Carcinoma27
2 Neoplasm of the Parathyroid Gland27

Anatomical Context for Parathyroid Carcinoma

About this section

MalaCards organs/tissues related to Parathyroid Carcinoma:

36
Bone, Thyroid, Lung, Lymph node, Brain, Liver, Breast

FMA organs/tissues related to Parathyroid Carcinoma:

17
The parathyroid gl

Publications for Parathyroid Carcinoma

About this section

Articles related to Parathyroid Carcinoma:

(show top 50)    (show all 519)
idTitleAuthorsYear
1
Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. (28458892)
2017
2
Giant parathyroid adenoma: differential aspects compared to parathyroid carcinoma. (28491324)
2017
3
Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. (28011856)
2017
4
Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. (28427885)
2017
5
Denosumab as a long-term palliative therapy in parathyroid carcinoma. (28011854)
2017
6
A nationwide study on parathyroid carcinoma. (28362521)
2017
7
Spontaneous bilateral quadriceps tendon rupture revealing a parathyroid carcinoma. (28115266)
2017
8
18F-FDG PET/CT Osteometabolic Activity in Metastatic Parathyroid Carcinoma. (27276208)
2016
9
Multiple brown tumours from parathyroid carcinoma. (27358103)
2016
10
Pathologic Fracture of the Femur in Brown Tumor Induced in Parathyroid Carcinoma: A Case Report. (27777921)
2016
11
Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. (27609904)
2016
12
Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. (27679651)
2016
13
Oncologic progress for the treatment of parathyroid carcinoma is needed. (27753088)
2016
14
Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. (27252748)
2016
15
Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. (26939543)
2016
16
A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature. (27544721)
2016
17
Controversies in the management of parathyroid carcinoma: A case series and review of the literature. (26708847)
2016
18
Parathyroid carcinoma in tertiary hyperparathyroidism. (27664600)
2016
19
Parathyroid carcinoma presenting as mandibular ulceration. (26895764)
2016
20
Is denosumab a long-term option for the treatment of parathyroid carcinoma? (26803154)
2016
21
Somatic HRPT2 Mutation (Arg234X) of Parathyroid Carcinoma Associated with Slipped Capital Femoral Epiphysis: A First Case Report. (27266237)
2016
22
Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?". (26803152)
2016
23
Parathyroid carcinoma with contralateral subcutaneous and breast recurrences: A rare presentation. (26685878)
2016
24
An unusual mediastinal parathyroid carcinoma coproducing PTH and PTHrP: A case report. (27313750)
2016
25
Association of parathyroid carcinoma and thyroid disorders: A clinical review. (27744598)
2016
26
A case of parathyroid carcinoma accompanied by a brown tumor. (27278852)
2016
27
Difficult management in parathyroid carcinoma with synchronous parathyroid hyperplasia. (27677089)
2016
28
Intrathyroidal parathyroid carcinoma. A case report and review of literature. (26588997)
2016
29
Intrathyroidal oxyphilic parathyroid carcinoma: A potential diagnostic caveat in cytology? (27229757)
2016
30
Parathyroid Carcinoma and Atypical Parathyroid Neoplasms in MEN1 Patients; A Clinico-Pathologic Challenge. The MD Anderson Case Series and Review of the Literature. (27212590)
2016
31
Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. (27250989)
2016
32
Parathyroid carcinoma. (26771263)
2016
33
Update on parathyroid carcinoma. (27001435)
2016
34
More Extensive Surgery May Not Improve Survival Over Parathyroidectomy Alone in Parathyroid Carcinoma. (27177488)
2016
35
Parathyroid Carcinoma: Is It Time for Change? (26100817)
2015
36
Parathyroid Carcinoma in a 10 Years Old Female Child. (26329966)
2015
37
Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. (25387265)
2015
38
Comment on: Is central lymph node dissection necessary for parathyroid carcinoma? (25921717)
2015
39
Brain metastases of parathyroid carcinoma: Review of the literature and a case report. (25690525)
2015
40
A Rare Constellation of HA1rthle Cell Thyroid Carcinoma and Parathyroid Carcinoma. (26813941)
2015
41
Parathyroid carcinoma: A report of six cases with a brief review of the literature. (26788136)
2015
42
Non-functional parathyroid carcinoma: a case report and review of the literature. (26408508)
2015
43
Parathyroid carcinoma: Diagnostic criteria, classification, evaluation. (25916757)
2015
44
Parathyroid Carcinoma: Diagnosis and Clinical Implications. (26177319)
2015
45
Establishment and characterization of a human parathyroid carcinoma derived cell line. (25655355)
2015
46
Is local resection sufficient for parathyroid carcinoma? (26017790)
2015
47
Pulmonary Embolism and Subclavian Vein Thrombosis in a Patient with Parathyroid Carcinoma: Case Report and Review of Literature. (26591405)
2015
48
Parathyroid carcinoma: Challenges in diagnosis and treatment. (25910997)
2015
49
Clinicopathological phenotype of parathyroid carcinoma. Therapeutic and prognostic aftermaths. (25800319)
2015
50
Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). (26077914)
2015

Variations for Parathyroid Carcinoma

About this section

Clinvar genetic disease variations for Parathyroid Carcinoma:

5 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1CDC73NM_ 024529.4(CDC73): c.766_ 767delGT (p.Val256Lysfs)deletionPathogenicrs80356650GRCh37Chr 1, 193117033: 193117034
2CDC73NM_ 024529.4(CDC73): c.687_ 688dupAG (p.Val230Glufs)duplicationPathogenicrs878855090GRCh37Chr 1, 193111154: 193111155
3CDC73NM_ 024529.4(CDC73): c.679_ 680insAG (p.Arg227Lysfs)insertionPathogenicrs80356649GRCh37Chr 1, 193111146: 193111147
4CDC73NM_ 024529.4(CDC73): c.128G> A (p.Trp43Ter)SNVPathogenicrs121434263GRCh37Chr 1, 193091458: 193091458
5CDC73NM_ 024529.4(CDC73): c.162C> G (p.Tyr54Ter)SNVPathogenicrs121434265GRCh37Chr 1, 193094272: 193094272
6CDC73CDC73, 1-BP INS, 373AinsertionPathogenic
7CDC73CDC73, 4-BP DEL, 685AGAGdeletionPathogenic
8CDC73NM_ 024529.4(CDC73): c.85delG (p.Glu29Serfs)deletionPathogenicrs587776560GRCh37Chr 1, 193091415: 193091415
9CDC73NM_ 024529.4(CDC73): c.13_ 30del18 (p.Leu5_ Gln10del)deletionPathogenicrs587776561GRCh37Chr 1, 193091343: 193091360
10CDC73NM_ 024529.4(CDC73): c.245delA (p.Asn82Ilefs)deletionPathogenicrs1060500009GRCh38Chr 1, 193130181: 193130181
11CDC73NM_ 024529.4(CDC73): c.237+1G> CSNVPathogenicrs794727303GRCh38Chr 1, 193125218: 193125218
12CDC73NM_ 024529.4(CDC73): c.729+1G> TSNVLikely pathogenicrs1060500012GRCh37Chr 1, 193111197: 193111197
13CDC73NM_ 024529.4(CDC73): c.455_ 456delGA (p.Arg152Ilefs)deletionPathogenicrs1060500019GRCh38Chr 1, 193138116: 193138117
14CDC73NM_ 024529.4(CDC73): c.4delG (p.Ala2Argfs)deletionPathogenicrs1060500020GRCh38Chr 1, 193122204: 193122204
15CDC73NC_ 000001.11: g.(?_ 193130174)_ (193130243_ ?)deldeletionPathogenicGRCh37Chr 1, 193099304: 193099373
16CDC73NC_ 000001.11: g.(?_ 193203795)_ (193236356_ ?)dupduplicationLikely pathogenicGRCh38Chr 1, 193203795: 193236356

Expression for genes affiliated with Parathyroid Carcinoma

About this section
Search GEO for disease gene expression data for Parathyroid Carcinoma.

Pathways for genes affiliated with Parathyroid Carcinoma

About this section

GO Terms for genes affiliated with Parathyroid Carcinoma

About this section

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:00304249.3CALCA, CASR, UCHL1
2neuronal cell bodyGO:00430258.7CALCA, CASR, UCHL1

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1beta-catenin-TCF complex assemblyGO:190483710.3CDC73, MEN1
2negative regulation of epithelial cell proliferationGO:005068010.3CDC73, MEN1
3cellular response to glucose stimulusGO:007133310.3CASR, MEN1
4response to fibroblast growth factorGO:007177410.2CASR, PTH
5positive regulation of calcium ion importGO:009028010.2CASR, LGALS3
6adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.2CALCA, PTH
7response to calcium ionGO:005159210.1CASR, CCND1
8monocyte chemotaxisGO:000254810.0CALCA, LGALS3
9positive regulation of cAMP biosynthetic processGO:003081910.0CALCA, PTH
10positive regulation of ossificationGO:004577810.0CALCA, PTH
11cellular calcium ion homeostasisGO:00068749.8CALCA, CASR, PTH
12response to ischemiaGO:00029319.6CASR, UCHL1
13vasodilationGO:00423119.5CALCA, CASR
14negative regulation of transcription from RNA polymerase II promoterGO:00001229.3CCND1, CDC73, MEN1, PTH

Sources for Parathyroid Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet